Efficacy of omadacycline against escherichia coli in a mouse urinary tract infection model

Kavindra V. Singh; Barbara E. Murray

doi:10.1128/AAC.00269-21

Efficacy of omadacycline against escherichia coli in a mouse urinary tract infection model

Kavindra V. Singh, Barbara E. Murray

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

In a mouse urinary tract infection model, omadacycline (OMC) was comparable to gentamicin and better than ciprofloxacin (CIP) against a tetracycline-susceptible (TET-S), CIP-resistant (CIP-R) Escherichia coli strain. Gentamicin showed better efficacy than OMC against a TET-R, CIP-R E. coli strain, and OMC again showed better efficacy than CIP against this strain. OMC may warrant further study as a potential option for urinary tract infection treatment against CIP-R E. coli strains.

Original language	English (US)
Article number	e00269-21
Journal	Antimicrobial Agents and Chemotherapy
Volume	65
Issue number	7
DOIs	https://doi.org/10.1128/AAC.00269-21
State	Published - Jul 2021

Keywords

Escherichia coli
Mouse UTI
Omadacycline

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00269-21

Cite this

@article{7ba4f35d83cf48e0892f9db3a3453d4f,

title = "Efficacy of omadacycline against escherichia coli in a mouse urinary tract infection model",

abstract = "In a mouse urinary tract infection model, omadacycline (OMC) was comparable to gentamicin and better than ciprofloxacin (CIP) against a tetracycline-susceptible (TET-S), CIP-resistant (CIP-R) Escherichia coli strain. Gentamicin showed better efficacy than OMC against a TET-R, CIP-R E. coli strain, and OMC again showed better efficacy than CIP against this strain. OMC may warrant further study as a potential option for urinary tract infection treatment against CIP-R E. coli strains.",

keywords = "Escherichia coli, Mouse UTI, Omadacycline",

author = "Singh, {Kavindra V.} and Murray, {Barbara E.}",

note = "Funding Information: This work was supported by Paratek Pharmaceuticals in the form of an investigator-initiated grant to the University of Texas Health Science Center, McGovern Medical School (K.V.S., principal investigator). B.E.M. and K.V.S. were supported in part by grant R21AI133289-01A1 from the NIAID. We thank Karen Jacques-Palaz for technical assistance. Publisher Copyright: {\textcopyright} 2021 American Society for Microbiology.",

year = "2021",

month = jul,

doi = "10.1128/AAC.00269-21",

language = "English (US)",

volume = "65",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - Efficacy of omadacycline against escherichia coli in a mouse urinary tract infection model

AU - Singh, Kavindra V.

AU - Murray, Barbara E.

N1 - Funding Information: This work was supported by Paratek Pharmaceuticals in the form of an investigator-initiated grant to the University of Texas Health Science Center, McGovern Medical School (K.V.S., principal investigator). B.E.M. and K.V.S. were supported in part by grant R21AI133289-01A1 from the NIAID. We thank Karen Jacques-Palaz for technical assistance. Publisher Copyright: © 2021 American Society for Microbiology.

PY - 2021/7

Y1 - 2021/7

N2 - In a mouse urinary tract infection model, omadacycline (OMC) was comparable to gentamicin and better than ciprofloxacin (CIP) against a tetracycline-susceptible (TET-S), CIP-resistant (CIP-R) Escherichia coli strain. Gentamicin showed better efficacy than OMC against a TET-R, CIP-R E. coli strain, and OMC again showed better efficacy than CIP against this strain. OMC may warrant further study as a potential option for urinary tract infection treatment against CIP-R E. coli strains.

AB - In a mouse urinary tract infection model, omadacycline (OMC) was comparable to gentamicin and better than ciprofloxacin (CIP) against a tetracycline-susceptible (TET-S), CIP-resistant (CIP-R) Escherichia coli strain. Gentamicin showed better efficacy than OMC against a TET-R, CIP-R E. coli strain, and OMC again showed better efficacy than CIP against this strain. OMC may warrant further study as a potential option for urinary tract infection treatment against CIP-R E. coli strains.

KW - Escherichia coli

KW - Mouse UTI

KW - Omadacycline

UR - http://www.scopus.com/inward/record.url?scp=85108152906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108152906&partnerID=8YFLogxK

U2 - 10.1128/AAC.00269-21

DO - 10.1128/AAC.00269-21

M3 - Article

C2 - 33972239

AN - SCOPUS:85108152906

SN - 0066-4804

VL - 65

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 7

M1 - e00269-21

ER -

Efficacy of omadacycline against escherichia coli in a mouse urinary tract infection model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this